Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. [electronic resource]
Producer: 20050713Description: 4573-5 p. digitalISSN:- 0006-4971
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Chromosome Aberrations
- Chromosomes, Human, Pair 7
- Combined Modality Therapy
- DNA Damage
- Dexamethasone -- administration & dosage
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Immunotherapy -- methods
- Interferon-alpha -- administration & dosage
- Leukemia, Myeloid, Acute -- chemically induced
- Lymphoma -- drug therapy
- Male
- Middle Aged
- Mitoxantrone -- administration & dosage
- Monosomy
- Myelodysplastic Syndromes -- chemically induced
- Remission Induction
- Rituximab
- Time Factors
- Vidarabine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.